Merck Goes Two For Three In The Big Easy
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is refining its arguments in Vioxx cases, though unpredictable juries remain a concern.
You may also be interested in...
Merck To Request New Trial On Liability Following Judge’s Vioxx Decision
New Orleans federal court judge overturns a jury decision awarding $51 mil. in damages in a Vioxx liability suit, calling the amount "excessive."
Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.
Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Exec discusses the firm’s pulmonary arterial hypertension drug Tracleer and other endothelin receptor antagonists in Actelion’s pipeline.